Sharda Cropchem Limited announced that its officials will attend the Anand Rathi Annual Flagship Conference G-200 Summit 2026. The event is scheduled for September 21, 2026, at the Taj Santacruz in Mumbai.

The company disclosed this engagement pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015. The meeting is set to take place from 10:00 am to 1:00 pm.

Meeting Details

The interaction with institutional investors and analysts will focus on publicly available information. The company explicitly stated that no unpublished price-sensitive information (UPSI) is intended to be discussed during the session.

Jetkin Gudhka, Company Secretary and Compliance Officer, signed the intimation issued on September 1, 2026. The notice also noted that changes to the schedule may occur due to exigencies on the part of the host or the company.

Sharda Cropchem released the transcript of its Q1FY27 earnings call, revealing that consolidated revenue rose 9% year-on-year to ₹1,074 crore while net profit fell 38% to ₹88 crore. The profit decline was primarily driven by a sharp reduction in unrealized foreign exchange (forex) gains, which dropped from ₹73.1 crore in Q1FY26 to ₹7.5 crore in Q1FY27. Despite the bottom-line impact, operational metrics strengthened significantly, with EBITDA growing 25% to ₹178 crore and gross margins expanding by 120 basis points to 36.7%.

Financial Performance and Operational Metrics

The company’s operating performance showed clear improvement during the quarter, insulated from the volatility affecting net profit. Revenue growth was fueled by strong performances in North America (NAFTA) and Latin America (LATAM), which offset an 11% decline in European revenues attributed to unusual heatwave conditions and distributor destocking. On a like-to-like basis, excluding forex impacts, profit before tax (PBT) grew 16% year-on-year to ₹111 crore, reflecting underlying business strength.

Agrochemical business revenue grew 8% to ₹915 crore, while non-agrochemical segments rose 15% to ₹159 crore. EBITDA margins expanded by 220 basis points to 16.6%, driven by favorable product mix and pricing power in high-value molecules.

Regional Dynamics and Margin Analysis

Regional performance varied significantly. Europe, traditionally a high-margin market, saw volume softening but maintained robust gross margins of 44.2%, up from 42.9% in Q1FY26. In contrast, NAFTA gross margins improved sharply to 32.8% from 25.9%, while LATAM margins contracted to 16.9% from 28%, despite strong volume growth. Management noted that distributor restocking in Europe has normalized as weather conditions stabilize.

Chairman and Managing Director R.V. Bubna highlighted that new product registrations continue to drive margin expansion. As of June 30, 2026, the company held 3,016 product registrations globally, up from 3,011 in March 2026, with an additional 1,027 applications pending approval.

Balance Sheet and Guidance

Sharda Cropchem remains debt-free with cash, bank balances, and liquid investments totaling ₹767 crore as of June 30, 2026, compared to ₹702 crore at the end of FY26. Total equity stood at ₹3,245 crore. Working capital days improved by 10 days to 88 days.

Management reaffirmed its FY27 guidance, targeting 10–15% revenue growth and gross margins in the range of 35–37%. EBITDA margins are expected to remain between 18% and 20%. Capital expenditure for the year is projected at ₹500–550 crore, with higher-than-expected Q1 spend attributed to data compensation costs for registrations.

What the Numbers Show

The divergence between reported net profit and operational metrics underscores the significant impact of unrealized forex movements on Sharda Cropchem’s bottom line. While the company disclosed that Q1FY26 included an exceptional ₹73.1 crore unrealized gain due to a 10% Euro-USD appreciation, Q1FY27 saw only a 1% movement, resulting in minimal forex gains. This volatility highlights the need for investors to assess performance on a like-to-like basis, where underlying profitability actually expanded by 16%. The sustained margin expansion despite volume de-growth of -1.6% indicates successful execution of its high-value product strategy.